This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2013 Jan 12;381(9861):95-6.

doi: 10.1016/S0140-6736(12)61221-5. Epub 2012 Nov 14.

Everolimus for astrocytomas in tuberous sclerosis complex

Birgit Geoerger¹, Heike Blockus

Affiliations

PMID: 23158521
DOI: 10.1016/S0140-6736(12)61221-5

Comment

Everolimus for astrocytomas in tuberous sclerosis complex

Birgit Geoerger et al. Lancet. 2013.

. 2013 Jan 12;381(9861):95-6.

doi: 10.1016/S0140-6736(12)61221-5. Epub 2012 Nov 14.

Authors

Birgit Geoerger¹, Heike Blockus

Affiliation

¹ Institut Gustave Roussy, Paediatrie, CNRS UMR8203, Villejuif 94805, France. geoerger@igr.fr

PMID: 23158521
DOI: 10.1016/S0140-6736(12)61221-5

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial.
Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S. Franz DN, et al. Lancet. 2013 Jan 12;381(9861):125-32. doi: 10.1016/S0140-6736(12)61134-9. Epub 2012 Nov 14. Lancet. 2013. PMID: 23158522 Clinical Trial.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information